Articles > Insulins & Non-insulins
The bill would mandate that the government negotiate with drug makers about the price of insulin, both in the Medicare program and for the open insurance market. It also includes many other mechanisms intended to lower the price of insulin and other drugs.
Four insurers have introduced a cap on monthly insulin costs, but the federal government’s move to change regulations around high-deductible insurance plans may have the biggest long-term impact.
The inaugural Northern California Center for Excellence will bring together key diabetes researchers investigators involved in diabetes cellular therapy and immune system research from Stanford University and UCSF.